Affimed validates antibody target for cancer metastasis

14-May-2008

Affimed Therapeutics AG announced that a collaboration with Dr. Stefan Weiss at the Institute of biochemistry of the Ludwig Maximilian University in Munich has strongly validated a target for cancer metastases amenable to the development of antibodies or other therapeutic interventions. The target, 37 kDa/67 kDa laminin receptor precursor and/ or its receptor, is overexpressed in cancer cell lines and their metastatic potential correlates with LRP/LR levels. Affimed was able to demonstrate that an antibody targeting this receptor could reduce invasive potential by up to 40% and adhesion by up to 70%.

LRP/LR acts as a receptor for prions and viruses, but has also been shown to be overexpressed in metastatic cancer tissue. In the present study, it was challenged in a metastatic cancer cell line with a variety of therapeutic strategies including single chain and full IgG antibodies, siRNAs and small molecules (polysulfated glycanes).The effects on the invasive and adhesive properties of the cells were examined using in vitro models of cell migration. Invasion and adhesion are the processes by which cancer cells metastasize and spread to multiple other regions of the body. The single chain and full length antibodies were able to reduce invasion by 30% and 40%, respectively, and adhesion by 60% and 70%, respectively.

Prof. Melvyn Little, CSO of Affimed commented: "Our data suggest that reagents directed against LRP/LR, in particular antibodies, might be potential cancer therapeutics blocking metastases. Once again we have been able to demonstrate Affimed's competence in generating new, fully human antibodies against innovative targets."

Original publication: Zuber, C., Knackmuss, S., Zemora , G., Reusch, U., Vlasova, E., Diehl, D., Mick , V., Hofmann, K., Nikles, D., Fröhlich, T., Arnold, G., Brenig, B., Wolf, E., Lahm, H., Little, M., & Weiss, S.; "Invasion of tumorigenic HT1080 cells is impeded by blocking or downregulating the 37 kDa/67 kDa laminin receptor."; Journal of Molecular Biology 2008, Volume 378, Issue 3, Pages 530-539.

Other news from the department research and development

These products might interest you

Micro-Dx™ CE IVD

Micro-Dx™ CE IVD by Molzym

Fully automated from sample to PCR analysis

Rapid identification of bacteria and fungi without time-consuming cultivation

DNA extraction kits
DNA-free Taq Polymerases and Mastermixes

DNA-free Taq Polymerases and Mastermixes by Molzym

DNA-free reagents for unrivalled sensitivity in molecular biology

Purity that makes the difference

PCR accessories
Greener Alternative Products

Greener Alternative Products by Merck Life Science

Sustainable laboratory products for environmentally conscious research

Over 2,500 ecological alternatives to reduce your laboratory footprint

consumables
CellGenix® Growth Factors and Cytokines

CellGenix® Growth Factors and Cytokines by Sartorius

Recombinant growth factors without animal products

Optimised cell culture for T cells and MSCs in gene therapy

reagents
Recombumin® Elite

Recombumin® Elite by Sartorius

ICHQ7 cGMP-compliant albumin for biotechnological applications

Increase consistency and safety for gene therapies and vaccines

reagents
DNA/RNA Shield™ SafeCollect Collection Kits

DNA/RNA Shield™ SafeCollect Collection Kits by Zymo Research

Sample collection devices for simple & safe at-home testing

Best user experience for secure self-collection

kits
Loading...

Most read news

More news from our other portals

All FT-IR spectrometer manufacturers at a glance

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Topic world Antibodies

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous